Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1866, Issue 2, 2016, Pages 266-275

  Ren, Fang ^a,b   Shen, Jacson ^b   Shi, Huirong ^a   Hornicek, Francis J ^b   Kan, Quancheng ^a   Duan, Zhenfeng ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autophagy; Cancer stem cells (CSCs); Multidrug resistance (MDR); Non coding RNA (ncRNA); Ovarian cancer; Tumor heterogeneity (TH)

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 MA; ADECATUMUMAB; BAFILOMYCIN A1; CARBOPLATIN; CATUMAXOMAB; CHLOROQUINE; CISPLATIN; DISULFIRAM; DOCETAXEL; DOXORUBICIN; FIRTECAN; GAMMA SECRETASE INHIBITOR; HYDROXYCHLOROQUINE; IMATINIB; LANIQUIDAR; N BENZYL 1,2,3,4,8,9 HEXAHYDRO 6 (4 HYDROXYBENZYL) 8 (1 NAPHTHYLMETHYL) 4,7 DIOXO 2H PYRAZINO[1,2 A]PYRIMIDINE 1(6H) CARBOXAMIDE; NSC 23925; NSC 73306; ONCOFID P; PACLITAXEL; PERIFOSINE; PROCYANIDIN; PROTEINASE INHIBITOR; TARIQUIDAR; TETRANDRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WORTMANNIN; ZOSUQUIDAR; MULTIDRUG RESISTANCE PROTEIN; UNTRANSLATED RNA;

AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL HETEROGENEITY; DOWN REGULATION; GENE LOCUS; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; OVARIAN NEOPLASMS;

AUTOPHAGY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; RNA, UNTRANSLATED;

EID: 84991510691     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2016.10.001     Document Type: Review

References (111)

1. [1] Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J. Clin. 60 (2010), 277–300.
2. [2] Mariotto, A., Howlader N, N.A., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., Kosary, C.L., M, Y., Ruhl, J., Tatalovich, Z., Lewis, D.R., Chen, H.S., Feuer, E.J., Cronin, K.A., (eds.) SEER Cancer Statistics Factsheets: Ovary Cancer, 2015, National Cancer Institute, Bethesda, MD.
3. [3] Liu, F.S., Mechanisms of chemotherapeutic drug resistance in cancer therapy–a quick review. Taiwan. J. Obstet. Gynecol. 48 (2009), 239–244.
4. [4] Verhaak, R.G., Tamayo, P., Yang, J.Y., Hubbard, D., Zhang, H., Creighton, C.J., Fereday, S., Lawrence, M., Carter, S.L., Mermel, C.H., Kostic, A.D., Etemadmoghadam, D., Saksena, G., Cibulskis, K., Duraisamy, S., Levanon, K., Sougnez, C., Tsherniak, A., Gomez, S., Onofrio, R., Gabriel, S., Chin, L., Zhang, N., Spellman, P.T., Zhang, Y., Akbani, R., Hoadley, K.A., Kahn, A., Kobel, M., Huntsman, D., Soslow, R.A., Defazio, A., Birrer, M.J., Gray, J.W., Weinstein, J.N., Bowtell, D.D., Drapkin, R., Mesirov, J.P., Getz, G., Levine, D.A., Meyerson, M., Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123 (2013), 517–525.
5. [5] Penson, R.T., Oliva, E., Skates, S.J., Glyptis, T., Fuller, A.F. Jr., Goodman, A., Seiden, M.V., Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol. Oncol. 93 (2004), 98–106.
6. [6] Wang, B., Li, S., Meng, X., Shang, H., Guan, Y., Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells. Tumour Biol. 36 (2015), 6433–6443.
7. [7] Glavinas, H., Krajcsi, P., Cserepes, J., Sarkadi, B., The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv. 1 (2004), 27–42.
8. [8] Palmeira, A., Sousa, E., Vasconcelos, M.H., Pinto, M.M., Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr. Med. Chem. 19 (2012), 1946–2025.
9. [9] Ozols, R.F., Cunnion, R.E., Klecker, R.W. Jr., Hamilton, T.C., Ostchega, Y., Parrillo, J.E., Young, R.C., Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5 (1987), 641–647.
10. [10] Rowinsky, E.K., Smith, L., Wang, Y.M., Chaturvedi, P., Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S.G., Hammond, L., Kraynak, M., Drengler, R., Stephenson, J. Jr., Harding, M.W., Von Hoff, D.D., Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 16 (1998), 2964–2976.
11. [11] Kelly, R.J., Draper, D., Chen, C.C., Robey, R.W., Figg, W.D., Piekarz, R.L., Chen, X., Gardner, E.R., Balis, F.M., Venkatesan, A.M., Steinberg, S.M., Fojo, T., Bates, S.E., A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin. Cancer Res. 17 (2011), 569–580.
12. [12] Ween, M.P., Armstrong, M.A., Oehler, M.K., Ricciardelli, C., The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit. Rev. Oncol. Hematol. 96 (2015), 220–256.
13. [13] Dai, C.L., Xiong, H.Y., Tang, L.F., Zhang, X., Liang, Y.J., Zeng, M.S., Chen, L.M., Wang, X.H., Fu, L.W., Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother. Pharmacol. 60 (2007), 741–750.
14. [14] Susa, M., Choy, E., Yang, C., Schwab, J., Mankin, H., Hornicek, F., Duan, Z., Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay. J. Biomol. Screen. 15 (2010), 287–296.
15. [15] Oldham, R.K., Reid, W.K., Preisler, H.D., Barnett, D., A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer. Cancer Biother. Radiopharm. 13 (1998), 71–80.
16. [16] Kelly, R.J., Robey, R.W., Chen, C.C., Draper, D., Luchenko, V., Barnett, D., Oldham, R.K., Caluag, Z., Frye, A.R., Steinberg, S.M., Fojo, T., Bates, S.E., A pharmacodynamic study of the P-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors. Oncologist, 17, 2012, 512.
17. [17] Ludwig, J.A., Szakacs, G., Martin, S.E., Chu, B.F., Cardarelli, C., Sauna, Z.E., Caplen, N.J., Fales, H.M., Ambudkar, S.V., Weinstein, J.N., Gottesman, M.M., Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 66 (2006), 4808–4815.
18. [18] Duan, Z., Choy, E., Hornicek, F.J., NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One, 4, 2009, e7415.
19. [19] Yang, X., Feng, Y., Gao, Y., Shen, J., Choy, E., Cote, G., Harmon, D., Zhang, Z., Mankin, H., Hornicek, F.J., Duan, Z., NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Gynecol. Oncol. 137 (2015), 134–142.
20. [20] Yang, X., Shen, J., Gao, Y., Feng, Y., Guan, Y., Zhang, Z., Mankin, H., Hornicek, F.J., Duan, Z., Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. Int. J. Cancer (Trans.) Journal international du cancer, 137, 2015, 2029–2039.
21. [21] Gao, Y., Shen, J.K., Choy, E., Zhang, Z., Mankin, H.J., Hornicek, F.J., Duan, Z., Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats. Sci. Rep., 6, 2016, 25659.
22. [22] Zhao, B.X., Sun, Y.B., Wang, S.Q., Duan, L., Huo, Q.L., Ren, F., Li, G.F., Grape seed procyanidin reversal of p-glycoprotein associated multi-drug resistance via down-regulation of NF-kappaB and MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One, 8, 2013, e71071.
23. [23] Wintzell, M., Hjerpe, E., Avall Lundqvist, E., Shoshan, M., Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer, 12, 2012, 359.
24. [24] Chen, R., Nishimura, M.C., Bumbaca, S.M., Kharbanda, S., Forrest, W.F., Kasman, I.M., Greve, J.M., Soriano, R.H., Gilmour, L.L., Rivers, C.S., Modrusan, Z., Nacu, S., Guerrero, S., Edgar, K.A., Wallin, J.J., Lamszus, K., Westphal, M., Heim, S., James, C.D., VandenBerg, S.R., Costello, J.F., Moorefield, S., Cowdrey, C.J., Prados, M., Phillips, H.S., A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17 (2010), 362–375.
25. [25] Gupta, P.B., Chaffer, C.L., Weinberg, R.A., Cancer stem cells: mirage or reality?. Nat. Med. 15 (2009), 1010–1012.
26. [26] Clevers, H., The cancer stem cell: premises, promises and challenges. Nat. Med. 17 (2011), 313–319.
27. [27] Steffensen, K.D., Alvero, A.B., Yang, Y., Waldstrom, M., Hui, P., Holmberg, J.C., Silasi, D.A., Jakobsen, A., Rutherford, T., Mor, G., Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J. Oncol., 2011, 2011, 620523.
28. [28] Silva, I.A., Bai, S., McLean, K., Yang, K., Griffith, K., Thomas, D., Ginestier, C., Johnston, C., Kueck, A., Reynolds, R.K., Wicha, M.S., Buckanovich, R.J., Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71 (2011), 3991–4001.
29. [29] Yasuda, K., Torigoe, T., Morita, R., Kuroda, T., Takahashi, A., Matsuzaki, J., Kochin, V., Asanuma, H., Hasegawa, T., Saito, T., Hirohashi, Y., Sato, N., Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS One, 8, 2013, e68187.
30. [30] Ricci, F., Bernasconi, S., Porcu, L., Erba, E., Panini, N., Fruscio, R., Sina, F., Torri, V., Broggini, M., Damia, G., ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am. J. Cancer Res. 3 (2013), 221–229.
31. [31] Ahmed, N., Abubaker, K., Findlay, J., Quinn, M., Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J. Cell. Biochem. 114 (2013), 21–34.
32. [32] Zhou, Q., Chen, A., Song, H., Tao, J., Yang, H., Zuo, M., Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. Int. J. Clin. Exp. Med. 8 (2015), 3080–3088.
33. [33] Irollo, E., Pirozzi, G., CD133: to be or not to be, is this the real question?. Am. J. Transl. Res. 5 (2013), 563–581.
34. [34] Gao, Y., Foster, R., Yang, X., Feng, Y., Shen, J.K., Mankin, H.J., Hornicek, F.J., Amiji, M.M., Duan, Z., Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget 6 (2015), 9313–9326.
35. [35] Bonneau, C., Rouzier, R., Geyl, C., Cortez, A., Castela, M., Lis, R., Darai, E., Touboul, C., Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. Gynecol. Oncol. 136 (2015), 112–120.
36. [36] Lee, M., Prognostic impact of epithelial cell adhesion molecule in ovarian cancer patients. J. Gynecol. Oncol. 25 (2014), 352–354.
37. [37] Woopen, H., Pietzner, K., Richter, R., Fotopoulou, C., Joens, T., Braicu, E.I., Mellstedt, H., Mahner, S., Lindhofer, H., Darb-Esfahani, S., Denkert, C., Sehouli, J., Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. J. Gynecol. Oncol. 25 (2014), 221–228.
38. [38] Richter, C.E., Cocco, E., Bellone, S., Silasi, D.A., Ruttinger, D., Azodi, M., Schwartz, P.E., Rutherford, T.J., Pecorelli, S., Santin, A.D., High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am. J. Obstet. Gynecol. 203 (2010), 582.e581–582.e587.
39. [39] Zhang, Q.H., Dou, H.T., Xu, P., Zhuang, S.C., Liu, P.S., Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer. Drug Res. 65 (2015), 153–157.
40. [40] Kobayashi, Y., Seino, K., Hosonuma, S., Ohara, T., Itamochi, H., Isonishi, S., Kita, T., Wada, H., Kojo, S., Kiguchi, K., Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. Gynecol. Oncol. 121 (2011), 390–394.
41. [41] Abubaker, K., Latifi, A., Luwor, R., Nazaretian, S., Zhu, H., Quinn, M.A., Thompson, E.W., Findlay, J.K., Ahmed, N., Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol. Cancer, 12, 2013, 24.
42. [42] Nagaraj, A.B., Joseph, P., Kovalenko, O., Singh, S., Armstrong, A., Redline, R., Resnick, K., Zanotti, K., Waggoner, S., DiFeo, A., Critical Role of Wnt/Beta-Catenin Signaling in Driving Epithelial Ovarian Cancer Platinum Resistance,Oncotarget. 2015.
43. [43] Anastas, J.N., Moon, R.T., WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13 (2013), 11–26.
44. [44] Morgan, S.L., Wyant, G.A., Dinulescu, D.M., “Take it up a NOTCH”: novel strategies for cancer therapy. Cell cycle (Georgetown, Tex.) 12 (2013), 191–192.
45. [45] McAuliffe, S.M., Morgan, S.L., Wyant, G.A., Tran, L.T., Muto, K.W., Chen, Y.S., Chin, K.T., Partridge, J.C., Poole, B.B., Cheng, K.H., Daggett, J. Jr., Cullen, K., Kantoff, E., Hasselbatt, K., Berkowitz, J., Muto, M.G., Berkowitz, R.S., Aster, J.C., Matulonis, U.A., Dinulescu, D.M., Targeting notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2939–E2948.
46. [46] Kwon, M.J., Shin, Y.K., Regulation of ovarian cancer stem cells or tumor-initiating cells. Int. J. Mol. Sci. 14 (2013), 6624–6648.
47. [47] Zhang, W., Liu, Y., Sun, N., Wang, D., Boyd-Kirkup, J., Dou, X., Han, J.D., Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. Cell Rep. 4 (2013), 542–553.
48. [48] Chau, W.K., Ip, C.K., Mak, A.S., Lai, H.C., Wong, A.S., c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 32 (2013), 2767–2781.
49. [49] Steg, A.D., Katre, A.A., Goodman, B., Han, H.D., Nick, A.M., Stone, R.L., Coleman, R.L., Alvarez, R.D., Lopez-Berestein, G., Sood, A.K., Landen, C.N., Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin. Cancer Res. 17 (2011), 5674–5685.
50. [50] De Stefano, I., Battaglia, A., Zannoni, G.F., Prisco, M.G., Fattorossi, A., Travaglia, D., Baroni, S., Renier, D., Scambia, G., Ferlini, C., Gallo, D., Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother. Pharmacol. 68 (2011), 107–116.
51. [51] Montagner, I.M., Merlo, A., Carpanese, D., Zuccolotto, G., Renier, D., Campisi, M., Pasut, G., Zanovello, P., Rosato, A., Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer. Oncoscience 2 (2015), 373–381.
52. [52] Umebayashi, M., Kiyota, A., Koya, N., Tanaka, H., Onishi, H., Katano, M., Morisaki, T., An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro. Anticancer Res. 34 (2014), 4509–4519.
53. [53] Tsikouras, P., Tsagias, N., Pinidis, P., Csorba, R., Vrachnis, N., Dafopoulos, A., Bouchlariotou, S., Liberis, A., Teichmann, A.T., von Tempelhoff, G.F., The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature. Arch. Gynecol. Obstet. 288 (2013), 581–585.
54. [54] Berek, J.S., Edwards, R.P., Parker, L.P., DeMars, L.R., Herzog, T.J., Lentz, S.S., Morris, R.T., Akerley, W.L., Holloway, R.W., Method, M.W., Plaxe, S.C., Walker, J.L., Friccius-Quecke, H., Krasner, C.N., Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int. J. Gynecol. Cancer 24 (2014), 1583–1589.
55. [55] Garcia Campelo, M.R., Alonso Curbera, G., Aparicio Gallego, G., Grande Pulido, E., Anton Aparicio, L.M., Stem cell and lung cancer development: blaming the Wnt. Hh and Notch Signalling Pathway, Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 13 (2011), 77–83.
56. [56] Groeneweg, J.W., DiGloria, C.M., Yuan, J., Richardson, W.S., Growdon, W.B., Sathyanarayanan, S., Foster, R., Rueda, B.R., Inhibition of notch signaling in combination with paclitaxel reduces platinum-resistant ovarian tumor growth. Front. Oncol., 4, 2014, 171.
57. [57] Gutschner, T., Diederichs, S., The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 9 (2012), 703–719.
58. [58] Sana, J., Faltejskova, P., Svoboda, M., Slaby, O., Novel classes of non-coding RNAs and cancer. J. Transl. Med., 10, 2012, 103.
59. [59] Chan, J.K., Blansit, K., Kiet, T., Sherman, A., Wong, G., Earle, C., Bourguignon, L.Y., The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol. Oncol. 132 (2014), 739–744.
60. [60] Frederick, P.J., Green, H.N., Huang, J.S., Egger, M.E., Frieboes, H.B., Grizzle, W.E., McNally, L.R., Chemoresistance in ovarian cancer linked to expression of microRNAs. Biotech. Histochem. 88 (2013), 403–409.
61. [61] Li, N., Yang, L., Wang, H., Yi, T., Jia, X., Chen, C., Xu, P., MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells. PLoS One, 10, 2015, e0128886.
62. [62] Li, H., Xu, H., Shen, H., Li, H., microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol. Lett. 7 (2014), 183–188.
63. [63] Kong, F., Sun, C., Wang, Z., Han, L., Weng, D., Lu, Y., Chen, G., miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1, journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying de wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 31 (2011), 543–549.
64. [64] Xiang, Y., Ma, N., Wang, D., Zhang, Y., Zhou, J., Wu, G., Zhao, R., Huang, H., Wang, X., Qiao, Y., Li, F., Han, D., Wang, L., Zhang, G., Gao, X., MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 33 (2014), 378–386.
65. [65] Huh, J.H., Kim, T.H., Kim, K., Song, J.A., Jung, Y.J., Jeong, J.Y., Lee, M.J., Kim, Y.K., Lee, D.H., An, H.J., Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br. J. Cancer 109 (2013), 452–461.
66. [66] Li, X., Pan, Q., Wan, X., Mao, Y., Lu, W., Xie, X., Cheng, X., Methylation-associated has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma. BMC Cancer, 15, 2015, 509.
67. [67] Chen, Q., Qin, R., Fang, Y., Li, H., Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway. Cell. Physiol. Biochem. 36 (2015), 956–965.
68. [68] van Jaarsveld, M.T., Helleman, J., Boersma, A.W., van Kuijk, P.F., van Ijcken, W.F., Despierre, E., Vergote, I., Mathijssen, R.H., Berns, E.M., Verweij, J., Pothof, J., Wiemer, E.A., miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 32 (2013), 4284–4293.
69. [69] Wang, Y.Q., Guo, R.D., Guo, R.M., Sheng, W., Yin, L.R., MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J. Cell. Biochem. 114 (2013), 1464–1473.
70. [70] Cheng, W., Liu, T., Wan, X., Gao, Y., Wang, H., MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 279 (2012), 2047–2059.
71. [71] Wang, Z., Liu, Q., Gao, Q., Luo, Y., Li, Q., Chen, J., Involvement of miR-199a in cisplatin resistance of ovarian cancer cell through modulating expression of mTOR. Zhonghua Yi Xue Za Zhi 95 (2015), 2705–2708.
72. [72] Ye, G., Fu, G., Cui, S., Zhao, S., Bernaudo, S., Bai, Y., Ding, Y., Zhang, Y., Yang, B.B., Peng, C., MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J. Cell Sci. 124 (2011), 359–368.
73. [73] Weiner-Gorzel, K., Dempsey, E., Milewska, M., McGoldrick, A., Toh, V., Walsh, A., Lindsay, S., Gubbins, L., Cannon, A., Sharpe, D., O'Sullivan, J., Murphy, M., Madden, S.F., Kell, M., McCann, A., Furlong, F., Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med. 4 (2015), 745–758.
74. [74] Pink, R.C., Samuel, P., Massa, D., Caley, D.P., Brooks, S.A., Carter, D.R., The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol. Oncol. 137 (2015), 143–151.
75. [75] Furlong, F., Fitzpatrick, P., O'Toole, S., Phelan, S., McGrogan, B., Maguire, A., O'Grady, A., Gallagher, M., Prencipe, M., McGoldrick, A., McGettigan, P., Brennan, D., Sheils, O., Martin, C., W.K., E., O'Leary, J., McCann, A., Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. J. Pathol. 226 (2012), 746–755.
76. [76] Boyerinas, B., Park, S.M., Murmann, A.E., Gwin, K., Montag, A.G., Zillhardt, M., Hua, Y.J., Lengyel, E., Peter, M.E., Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int. J. Cancer (Trans.) Journal international du cancer, 130, 2012, 1787–1797.
77. [77] Sun, C., Li, N., Yang, Z., Zhou, B., He, Y., Weng, D., Fang, Y., Wu, P., Chen, P., Yang, X., Ma, D., Zhou, J., Chen, G., miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J. Natl. Cancer Inst. 105 (2013), 1750–1758.
78. [78] Mitamura, T., Watari, H., Wang, L., Kanno, H., Hassan, M.K., Miyazaki, M., Katoh, Y., Kimura, T., Tanino, M., Nishihara, H., Tanaka, S., Sakuragi, N., Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis, 2, 2013, e40.
79. [79] Yang, C., Cai, J., Wang, Q., Tang, H., Cao, J., Wu, L., Wang, Z., Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol. Oncol. 124 (2012), 325–334.
80. [80] Liu, M.X., Siu, M.K., Liu, S.S., Yam, J.W., Ngan, H.Y., Chan, D.W., Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 5 (2014), 944–958.
81. [81] Cittelly, D.M., Dimitrova, I., Howe, E.N., Cochrane, D.R., Jean, A., Spoelstra, N.S., Post, M.D., Lu, X., Broaddus, R.R., Spillman, M.A., Richer, J.K., Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol. Cancer Ther. 11 (2012), 2556–2565.
82. [82] Wang, Y.S., Wang, Y.H., Xia, H.P., Zhou, S.W., Schmid-Bindert, G., Zhou, C.C., MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac. J. Cancer Prev. 13 (2012), 255–260.
83. [83] Redis, R.S., Sieuwerts, A.M., Look, M.P., Tudoran, O., Ivan, C., Spizzo, R., Zhang, X., de Weerd, V., Shimizu, M., Ling, H., Buiga, R., Pop, V., Irimie, A., Fodde, R., Bedrosian, I., Martens, J.W., Foekens, J.A., Berindan-Neagoe, I., Calin, G.A., CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget 4 (2013), 1748–1762.
84. [84] Zhao, M., Qiu, Y., Yang, B., Sun, L., Hei, K., Du, X., Li, Y., Long non-coding RNAs involved in gynecological cancer. Int. J. Gynecol. Cancer 24 (2014), 1140–1145.
85. [85] Tsai, M.C., Spitale, R.C., Chang, H.Y., Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res. 71 (2011), 3–7.
86. [86] Gupta, R.A., Shah, N., Wang, K.C., Kim, J., Horlings, H.M., Wong, D.J., Tsai, M.C., Hung, T., Argani, P., Rinn, J.L., Wang, Y., Brzoska, P., Kong, B., Li, R., West, R.B., van de Vijver, M.J., Sukumar, S., Chang, H.Y., Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464 (2010), 1071–1076.
87. [87] Qiu, J.J., Lin, Y.Y., Ye, L.C., Ding, J.X., Feng, W.W., Jin, H.Y., Zhang, Y., Li, Q., Hua, K.Q., Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. Gynecol. Oncol. 134 (2014), 121–128.
88. [88] Li, J., Yang, S., Su, N., Wang, Y., Yu, J., Qiu, H., He, X., Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/beta-catenin pathway in human ovarian cancer. Tumour Biol., 2015.
89. [89] Wu, D.I., Wang, T., Ren, C., Liu, L., Kong, D., Jin, X., Li, X., Zhang, G., Downregulation of BC200 in ovarian cancer contributes to cancer cell proliferation and chemoresistance to carboplatin. Oncol. Lett. 11 (2016), 1189–1194.
90. [90] Liu, E., Liu, Z., Zhou, Y., Mi, R., Wang, D., Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int. J. Clin. Exp. Med. 8 (2015), 20565–20572.
91. [91] Zhang, L., Cao, X., Zhang, L., Zhang, X., Sheng, H., Tao, K., UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy. Cancer Chemother. Pharmacol. 77 (2016), 629–634.
92. [92] Wang, F., Zhou, J., Xie, X., Hu, J., Chen, L., Hu, Q., Guo, H., Yu, C., Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma 62 (2015), 432–438.
93. [93] van Jaarsveld, M.T., van Kuijk, P.F., Boersma, A.W., Helleman, J., van, I.W.F., Mathijssen, R.H., Pothof, J., Berns, E.M., Verweij, J., Wiemer, E.A., miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol. Cancer, 14, 2015, 196.
94. [94] Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., Wang, X., He, C., Pan, H., Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis., 4, 2013, e838.
95. [95] Bao, L., Jaramillo, M.C., Zhang, Z., Zheng, Y., Yao, M., Zhang, D.D., Yi, X., Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells. Mol. Med. Rep. 11 (2015), 91–98.
96. [96] Bai, H., Li, H., Li, W., Gui, T., Yang, J., Cao, D., Shen, K., The PI3K/AKT/mTOR Pathway Is a Potential Predictor of Distinct Invasive and Migratory Capacities in Human Ovarian Cancer Cell Lines, Oncotarget. 2015.
97. [97] Bunkholt Elstrand, M., Dong, H.P., Odegaard, E., Holth, A., Elloul, S., Reich, R., Trope, C.G., Davidson, B., Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum. Pathol. 41 (2010), 794–804.
98. [98] Wang, J., Wu, G.S., Role of autophagy in cisplatin resistance in ovarian cancer cells. J. Biol. Chem. 289 (2014), 17163–17173.
99. [99] Zhao, X., Fang, Y., Yang, Y., Qin, Y., Wu, P., Wang, T., Lai, H., Meng, L., Wang, D., Zheng, Z., Lu, X., Zhang, H., Gao, Q., Zhou, J., Ma, D., Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells. Autophagy 11 (2015), 1849–1863.
100. [100] Nilsson, J.R., Does chloroquine, an antimalarial drug, affect autophagy in Tetrahymena pyriformis?. J. Protozool. 39 (1992), 9–16.
101. [101] Morgan, M.J., Gamez, G., Menke, C., Hernandez, A., Thorburn, J., Gidan, F., Staskiewicz, L., Morgan, S., Cummings, C., Maycotte, P., Thorburn, A., Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent. Autophagy 10 (2014), 1814–1826.
102. [102] Ying, H., Qu, D., Liu, C., Ying, T., Lv, J., Jin, S., Xu, H., Chemoresistance is associated with Beclin-1 and PTEN expression in epithelial ovarian cancers. Oncol. Lett. 9 (2015), 1759–1763.
103. [103] Lu, Z., Baquero, M.T., Yang, H., Yang, M., Reger, A.S., Kim, C., Levine, D.A., Clarke, C.H., Liao, W.S., Bast, R.C. Jr., DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy 10 (2014), 1071–1092.
104. [104] Feng, W., Marquez, R.T., Lu, Z., Liu, J., Lu, K.H., Issa, J.P., Fishman, D.M., Yu, Y., Bast, R.C. Jr., Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112 (2008), 1489–1502.
105. [105] Washington, M.N., Suh, G., Orozco, A.F., Sutton, M.N., Yang, H., Wang, Y., Mao, W., Millward, S., Ornelas, A., Atkinson, N., Liao, W., Bast, R.C. Jr., Lu, Z., ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death Dis., 6, 2015, e1836.
106. [106] Sui, H., Shi, C., Yan, Z., Li, H., Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Drug Des. Devel. Ther. 9 (2015), 3183–3190.
107. [107] Gerlinger, M., Swanton, C., How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103 (2010), 1139–1143.
108. [108] Patch, A.M., Christie, E.L., Etemadmoghadam, D., Garsed, D.W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P.J., Kassahn, K.S., Newell, F., Quinn, M.C., Kazakoff, S., Quek, K., Wilhelm-Benartzi, C., Curry, E., Leong, H.S., Hamilton, A., Mileshkin, L., Au-Yeung, G., Kennedy, C., Hung, J., Chiew, Y.E., Harnett, P., Friedlander, M., Quinn, M., Pyman, J., Cordner, S., O'Brien, P., Leditschke, J., Young, G., Strachan, K., Waring, P., Azar, W., Mitchell, C., Traficante, N., Hendley, J., Thorne, H., Shackleton, M., Miller, D.K., Arnau, G.M., Tothill, R.W., Holloway, T.P., Semple, T., Harliwong, I., Nourse, C., Nourbakhsh, E., Manning, S., Idrisoglu, S., Bruxner, T.J., Christ, A.N., Poudel, B., Holmes, O., Anderson, M., Leonard, C., Lonie, A., Hall, N., Wood, S., Taylor, D.F., Xu, Q., Fink, J.L., Waddell, N., Drapkin, R., Stronach, E., Gabra, H., Brown, R., Jewell, A., Nagaraj, S.H., Markham, E., Wilson, P.J., Ellul, J., McNally, O., Doyle, M.A., Vedururu, R., Stewart, C., Lengyel, E., Pearson, J.V., Waddell, N., deFazio, A., Grimmond, S.M., Bowtell, D.D., Whole-genome characterization of chemoresistant ovarian cancer. Nature 521 (2015), 489–494.
109. [109] Page, C., Lin, H.J., Jin, Y., Castle, V.P., Nunez, G., Huang, M., Lin, J., Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 20 (2000), 407–416.
110. [110] Zeller, C., Dai, W., Steele, N.L., Siddiq, A., Walley, A.J., Wilhelm-Benartzi, C.S., Rizzo, S., van der Zee, A., Plumb, J.A., Brown, R., Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31 (2012), 4567–4576.
111. [111] Fu, S., Hennessy, B.T., Ng, C.S., Ju, Z., Coombes, K.R., Wolf, J.K., Sood, A.K., Levenback, C.F., Coleman, R.L., Kavanagh, J.J., Gershenson, D.M., Markman, M., Dice, K., Howard, A., Li, J., Li, Y., Stemke-Hale, K., Dyer, M., Atkinson, E., Jackson, E., Kundra, V., Kurzrock, R., Bast, R.C. Jr., Mills, G.B., Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol. Oncol. 126 (2012), 47–53.